AI Science Tracker
EN

The First Affiliated Hospital of Bengbu Medical University

2 discoveries from 2025 to 2026

Discoveries

Development and validation of a habitat-based radiomics fusion model for predicting immunotherapy response in advanced NSCLC: a multicenter retrospective study.

Source check: Source checked. Not independent scientific confirmation.

Finding: Results support the represented result: Multicenter cohorts support radiomics prediction of immunotherapy response in advanced lung cancer. Interpretation remains limited to the reported study. Methods identify the case-specific learned operation: Multicenter cohorts support radiomics prediction of immunotherapy response in advanced lung cancer. Testing: The full text reports the case-specific data/cohort, comparison/reference and evaluation; no broader clinical benefit is inferred.. The primary full text supports the case-specific result: Multicenter cohorts support radiomics prediction of immunotherapy response in advanced lung cancer. Source affiliation was not stated in the reviewed case checks and was unavailable in the local bibliographic cache.

Technology: Methods identify the case-specific learned operation: Multicenter cohorts support radiomics prediction of immunotherapy response in advanced lung cancer.

Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.

AI contribution
Methods identify the case-specific learned operation: Multicenter cohorts support radiomics prediction of immunotherapy response in advanced lung cancer.
Test and result
The full text reports the case-specific data/cohort, comparison/reference and evaluation; no broader clinical benefit is inferred.
Limitation / still unknown
Generalizability beyond the reported study population, data, and protocol was not established in the reviewed material.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13740796/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Unraveling the role of histone acetylation in sepsis biomarker discovery

Source check: Source checked. Not independent scientific confirmation.

Finding: Histone-acetylation transcriptomic analysis using LASSO, SVM-RFE and Boruta nominated three sepsis biomarkers; follow-up patient-blood/qPCR, MR and THP-1 knockdown assays support SFT2D1’s relation to inflammatory cytokines. This is a bounded biomarker/mechanistic result, not clinical benefit. This record is limited to the study result and does not establish independent replication or real-world benefit.

Technology: LASSO, SVM-RFE and Boruta

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Methods 2.1-2.5 and Results: GEO training/validation plus scRNA-seq; LASSO, SVM-RFE and Boruta prioritize BLOC1S1/NDUFA1/SFT2D1; THP-1 knockdown reduces CXCL10 and IL-6; patient blood/qPCR and MR are additional validation.
Test and result
Histone-acetylation transcriptomic analysis using LASSO, SVM-RFE and Boruta nominated three sepsis biomarkers; follow-up patient-blood/qPCR, MR and THP-1 knockdown assays support SFT2D1’s relation to inflammatory cytokines. This is a bounded biomarker/mechanistic result, not clinical benefit.
Limitation / still unknown
No prospective clinical benefit or broader external validity is established by the documented study.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1582181/full

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.